Amylyx Pharmaceuticals, Inc. Common Stock represents ownership in a clinical-stage biopharmaceutical company dedicated to developing investigational therapies for neurodegenerative diseases and endocrine conditions. The company focuses on advancing its pipeline, including avexitide, a first-in-class GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism; AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol under investigation for Wolfram syndrome; AMX0114 in Phase 1 for amyotrophic lateral sclerosis; and AMX0318, a long-acting GLP-1 receptor antagonist candidate for post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals targets unmet needs in conditions like progressive supranuclear palsy, ALS, and endocrine disorders through clinical trials emphasizing safety, tolerability, and efficacy data. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company operates globally with subsidiaries supporting its research and development efforts in these critical therapeutic areas.